Bivalent Human Papillomavirus Vaccine Market contains market size and forecasts of Bivalent Human Papillomavirus Vaccine in global, including the following market information:
- Global Bivalent Human Papillomavirus Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Bivalent Human Papillomavirus Vaccine Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Bivalent Human Papillomavirus Vaccine companies in 2021 (%)
The global Bivalent Human Papillomavirus Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
HPV16 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bivalent Human Papillomavirus Vaccine include Merck & Co., Inc., GSK, INNOVAX, ZSSW, HUMANWELL HEALTHCARE, WALVAX and Serum Institute of India, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Bivalent Human Papillomavirus Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bivalent Human Papillomavirus Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bivalent Human Papillomavirus Vaccine Market Segment Percentages, by Type, 2021 (%)
Global Bivalent Human Papillomavirus Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bivalent Human Papillomavirus Vaccine Market Segment Percentages, by Application, 2021 (%)
- 9-16 Years Old
- 16-20 Years Old
- 20-26 Years Old
- 26-45 Years Old
Global Bivalent Human Papillomavirus Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bivalent Human Papillomavirus Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Bivalent Human Papillomavirus Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Bivalent Human Papillomavirus Vaccine revenues share in global market, 2021 (%)
- Key companies Bivalent Human Papillomavirus Vaccine sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Bivalent Human Papillomavirus Vaccine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Merck & Co., Inc.
- GSK
- INNOVAX
- ZSSW
- HUMANWELL HEALTHCARE
- WALVAX
- Serum Institute of India
Industry Market Size
